Nansan Houn/iStock via Getty Images
- Mirum Pharmaceuticals (MIRM) is off ~5% in Monday morning trading despite releasing data showing that brelovitug met its primary endpoint in a phase 3 study for chronic hepatitis delta virus.
- Results from the AZURE-1 study showed that patients on brelovitug
